Review




Structured Review

DSMZ s fradiae
Figure 5. Actinobacteria bearing divergent ribosomal drug-binding sites are intrinsi cally resistant to antibiotics (A) Schematic phylogenetic tree showing three closely related branches of Actinobacteria. Each branch exhibits nucleotide variations in the 16S rRNA sequence at the binding sites for two ribo some-targeting antibiotics—spectinomycin and paromomycin. (B–D) Comparison of minimum inhibitory concen trations (MICs) for pactamycin and spectinomycin across representative Actinobacteria, including S. <t>fradiae</t> (bears identical drug-binding residues to E. coli), M. smegmatis (bears A694G substitution in the pactamycin-binding site), and K. subterranea (bears C1192G substitution in the spectinomycin- binding site compared to E. coli). The images show that 16S rRNA nucleotide alterations—previously characterized as resistance conferring in model organisms—correlate with intrinsic drug suscepti bility. Specifically, K. subterranea, which carries the C1192G substitution in spectinomycin-binding site, exhibits intrinsic resistance to spectinomycin (MIC = 20,000 μg/mL), while M. smegmatis (lacking this substitution) exhibits spectinomycin sensitivity (MIC = 20 μg/mL). Conversely, M. smegmatis (bearing A694G substitution in the pactamycin- binding site) can tolerate pactamycin at 62.5 μg/mL concentration, which is 500× higher compared to the concentration required to inhibit the growth of K. subterranea (as shown in Figure S3).
S Fradiae, supplied by DSMZ, used in various techniques. Bioz Stars score: 93/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/s fradiae/product/DSMZ
Average 93 stars, based on 8 article reviews
s fradiae - by Bioz Stars, 2026-02
93/100 stars

Images

1) Product Images from "Extensive natural variation in bacterial ribosomal drug-binding sites."

Article Title: Extensive natural variation in bacterial ribosomal drug-binding sites.

Journal: Cell reports

doi: 10.1016/j.celrep.2025.115878

Figure 5. Actinobacteria bearing divergent ribosomal drug-binding sites are intrinsi cally resistant to antibiotics (A) Schematic phylogenetic tree showing three closely related branches of Actinobacteria. Each branch exhibits nucleotide variations in the 16S rRNA sequence at the binding sites for two ribo some-targeting antibiotics—spectinomycin and paromomycin. (B–D) Comparison of minimum inhibitory concen trations (MICs) for pactamycin and spectinomycin across representative Actinobacteria, including S. fradiae (bears identical drug-binding residues to E. coli), M. smegmatis (bears A694G substitution in the pactamycin-binding site), and K. subterranea (bears C1192G substitution in the spectinomycin- binding site compared to E. coli). The images show that 16S rRNA nucleotide alterations—previously characterized as resistance conferring in model organisms—correlate with intrinsic drug suscepti bility. Specifically, K. subterranea, which carries the C1192G substitution in spectinomycin-binding site, exhibits intrinsic resistance to spectinomycin (MIC = 20,000 μg/mL), while M. smegmatis (lacking this substitution) exhibits spectinomycin sensitivity (MIC = 20 μg/mL). Conversely, M. smegmatis (bearing A694G substitution in the pactamycin- binding site) can tolerate pactamycin at 62.5 μg/mL concentration, which is 500× higher compared to the concentration required to inhibit the growth of K. subterranea (as shown in Figure S3).
Figure Legend Snippet: Figure 5. Actinobacteria bearing divergent ribosomal drug-binding sites are intrinsi cally resistant to antibiotics (A) Schematic phylogenetic tree showing three closely related branches of Actinobacteria. Each branch exhibits nucleotide variations in the 16S rRNA sequence at the binding sites for two ribo some-targeting antibiotics—spectinomycin and paromomycin. (B–D) Comparison of minimum inhibitory concen trations (MICs) for pactamycin and spectinomycin across representative Actinobacteria, including S. fradiae (bears identical drug-binding residues to E. coli), M. smegmatis (bears A694G substitution in the pactamycin-binding site), and K. subterranea (bears C1192G substitution in the spectinomycin- binding site compared to E. coli). The images show that 16S rRNA nucleotide alterations—previously characterized as resistance conferring in model organisms—correlate with intrinsic drug suscepti bility. Specifically, K. subterranea, which carries the C1192G substitution in spectinomycin-binding site, exhibits intrinsic resistance to spectinomycin (MIC = 20,000 μg/mL), while M. smegmatis (lacking this substitution) exhibits spectinomycin sensitivity (MIC = 20 μg/mL). Conversely, M. smegmatis (bearing A694G substitution in the pactamycin- binding site) can tolerate pactamycin at 62.5 μg/mL concentration, which is 500× higher compared to the concentration required to inhibit the growth of K. subterranea (as shown in Figure S3).

Techniques Used: Binding Assay, Sequencing, Comparison, Concentration Assay

Figure 6. rRNA substitutions that cause drug resistance in model organisms are widespread among natural bacterial species (A) rRNA secondary structure diagrams illustrate divergence in the evernimicin-binding pocket between S. fradiae and E. coli ribosomes. (B) Cryo-EM map of S. fradiae shows the divergent drug-binding site. (C) Comparison of experimental and AlphaFold3-predicted structures of S. fradiae’s evernimicin-binding pocket reveals nearly identical conformations (all-atom RMSD = ∼0.3 A˚ ), validating AlphaFold’s utility for assessing rRNA substitution effects. (D) Superposition of vacant S. fradiae ribosome with evernimicin-bound E. coli structure. (E–P) Comparisons of wild-type E. coli binding sites with AlphaFold3-predicted divergent sites across species demonstrate how rRNA variation alters pocket conformation, with each box summarizing the reported drug affinity impacts of substitutions and phylogenetic distribution of variants. Asterisks indicate sequence variants that have a variable impact on drug affinity that depends on the surrounding context in rRNA. (E)–(J) correspond to the large subunit and (K)–(P) to the small subunit. Overall, (E)–(P) show that changes at the direct ribosome-drug interface—even in the absence of apparent steric clashes or disrupted hydrophobic stacking interactions—typically lead to resistance.
Figure Legend Snippet: Figure 6. rRNA substitutions that cause drug resistance in model organisms are widespread among natural bacterial species (A) rRNA secondary structure diagrams illustrate divergence in the evernimicin-binding pocket between S. fradiae and E. coli ribosomes. (B) Cryo-EM map of S. fradiae shows the divergent drug-binding site. (C) Comparison of experimental and AlphaFold3-predicted structures of S. fradiae’s evernimicin-binding pocket reveals nearly identical conformations (all-atom RMSD = ∼0.3 A˚ ), validating AlphaFold’s utility for assessing rRNA substitution effects. (D) Superposition of vacant S. fradiae ribosome with evernimicin-bound E. coli structure. (E–P) Comparisons of wild-type E. coli binding sites with AlphaFold3-predicted divergent sites across species demonstrate how rRNA variation alters pocket conformation, with each box summarizing the reported drug affinity impacts of substitutions and phylogenetic distribution of variants. Asterisks indicate sequence variants that have a variable impact on drug affinity that depends on the surrounding context in rRNA. (E)–(J) correspond to the large subunit and (K)–(P) to the small subunit. Overall, (E)–(P) show that changes at the direct ribosome-drug interface—even in the absence of apparent steric clashes or disrupted hydrophobic stacking interactions—typically lead to resistance.

Techniques Used: Binding Assay, Cryo-EM Sample Prep, Comparison, Sequencing



Similar Products

91
ATCC s fradiae atcc 14544
S Fradiae Atcc 14544, supplied by ATCC, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/s fradiae atcc 14544/product/ATCC
Average 91 stars, based on 1 article reviews
s fradiae atcc 14544 - by Bioz Stars, 2026-02
91/100 stars
  Buy from Supplier

93
DSMZ s fradiae
Figure 5. Actinobacteria bearing divergent ribosomal drug-binding sites are intrinsi cally resistant to antibiotics (A) Schematic phylogenetic tree showing three closely related branches of Actinobacteria. Each branch exhibits nucleotide variations in the 16S rRNA sequence at the binding sites for two ribo some-targeting antibiotics—spectinomycin and paromomycin. (B–D) Comparison of minimum inhibitory concen trations (MICs) for pactamycin and spectinomycin across representative Actinobacteria, including S. <t>fradiae</t> (bears identical drug-binding residues to E. coli), M. smegmatis (bears A694G substitution in the pactamycin-binding site), and K. subterranea (bears C1192G substitution in the spectinomycin- binding site compared to E. coli). The images show that 16S rRNA nucleotide alterations—previously characterized as resistance conferring in model organisms—correlate with intrinsic drug suscepti bility. Specifically, K. subterranea, which carries the C1192G substitution in spectinomycin-binding site, exhibits intrinsic resistance to spectinomycin (MIC = 20,000 μg/mL), while M. smegmatis (lacking this substitution) exhibits spectinomycin sensitivity (MIC = 20 μg/mL). Conversely, M. smegmatis (bearing A694G substitution in the pactamycin- binding site) can tolerate pactamycin at 62.5 μg/mL concentration, which is 500× higher compared to the concentration required to inhibit the growth of K. subterranea (as shown in Figure S3).
S Fradiae, supplied by DSMZ, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/s fradiae/product/DSMZ
Average 93 stars, based on 1 article reviews
s fradiae - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

93
ATCC s fradiae atcc 10745
Figure 5. Actinobacteria bearing divergent ribosomal drug-binding sites are intrinsi cally resistant to antibiotics (A) Schematic phylogenetic tree showing three closely related branches of Actinobacteria. Each branch exhibits nucleotide variations in the 16S rRNA sequence at the binding sites for two ribo some-targeting antibiotics—spectinomycin and paromomycin. (B–D) Comparison of minimum inhibitory concen trations (MICs) for pactamycin and spectinomycin across representative Actinobacteria, including S. <t>fradiae</t> (bears identical drug-binding residues to E. coli), M. smegmatis (bears A694G substitution in the pactamycin-binding site), and K. subterranea (bears C1192G substitution in the spectinomycin- binding site compared to E. coli). The images show that 16S rRNA nucleotide alterations—previously characterized as resistance conferring in model organisms—correlate with intrinsic drug suscepti bility. Specifically, K. subterranea, which carries the C1192G substitution in spectinomycin-binding site, exhibits intrinsic resistance to spectinomycin (MIC = 20,000 μg/mL), while M. smegmatis (lacking this substitution) exhibits spectinomycin sensitivity (MIC = 20 μg/mL). Conversely, M. smegmatis (bearing A694G substitution in the pactamycin- binding site) can tolerate pactamycin at 62.5 μg/mL concentration, which is 500× higher compared to the concentration required to inhibit the growth of K. subterranea (as shown in Figure S3).
S Fradiae Atcc 10745, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/s fradiae atcc 10745/product/ATCC
Average 93 stars, based on 1 article reviews
s fradiae atcc 10745 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

93
ATCC fluorescence p108 phage s aureus
Figure 5. Actinobacteria bearing divergent ribosomal drug-binding sites are intrinsi cally resistant to antibiotics (A) Schematic phylogenetic tree showing three closely related branches of Actinobacteria. Each branch exhibits nucleotide variations in the 16S rRNA sequence at the binding sites for two ribo some-targeting antibiotics—spectinomycin and paromomycin. (B–D) Comparison of minimum inhibitory concen trations (MICs) for pactamycin and spectinomycin across representative Actinobacteria, including S. <t>fradiae</t> (bears identical drug-binding residues to E. coli), M. smegmatis (bears A694G substitution in the pactamycin-binding site), and K. subterranea (bears C1192G substitution in the spectinomycin- binding site compared to E. coli). The images show that 16S rRNA nucleotide alterations—previously characterized as resistance conferring in model organisms—correlate with intrinsic drug suscepti bility. Specifically, K. subterranea, which carries the C1192G substitution in spectinomycin-binding site, exhibits intrinsic resistance to spectinomycin (MIC = 20,000 μg/mL), while M. smegmatis (lacking this substitution) exhibits spectinomycin sensitivity (MIC = 20 μg/mL). Conversely, M. smegmatis (bearing A694G substitution in the pactamycin- binding site) can tolerate pactamycin at 62.5 μg/mL concentration, which is 500× higher compared to the concentration required to inhibit the growth of K. subterranea (as shown in Figure S3).
Fluorescence P108 Phage S Aureus, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fluorescence p108 phage s aureus/product/ATCC
Average 93 stars, based on 1 article reviews
fluorescence p108 phage s aureus - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

95
ATCC s fradiae atcc 19609
Figure 5. Actinobacteria bearing divergent ribosomal drug-binding sites are intrinsi cally resistant to antibiotics (A) Schematic phylogenetic tree showing three closely related branches of Actinobacteria. Each branch exhibits nucleotide variations in the 16S rRNA sequence at the binding sites for two ribo some-targeting antibiotics—spectinomycin and paromomycin. (B–D) Comparison of minimum inhibitory concen trations (MICs) for pactamycin and spectinomycin across representative Actinobacteria, including S. <t>fradiae</t> (bears identical drug-binding residues to E. coli), M. smegmatis (bears A694G substitution in the pactamycin-binding site), and K. subterranea (bears C1192G substitution in the spectinomycin- binding site compared to E. coli). The images show that 16S rRNA nucleotide alterations—previously characterized as resistance conferring in model organisms—correlate with intrinsic drug suscepti bility. Specifically, K. subterranea, which carries the C1192G substitution in spectinomycin-binding site, exhibits intrinsic resistance to spectinomycin (MIC = 20,000 μg/mL), while M. smegmatis (lacking this substitution) exhibits spectinomycin sensitivity (MIC = 20 μg/mL). Conversely, M. smegmatis (bearing A694G substitution in the pactamycin- binding site) can tolerate pactamycin at 62.5 μg/mL concentration, which is 500× higher compared to the concentration required to inhibit the growth of K. subterranea (as shown in Figure S3).
S Fradiae Atcc 19609, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/s fradiae atcc 19609/product/ATCC
Average 95 stars, based on 1 article reviews
s fradiae atcc 19609 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

Image Search Results


Figure 5. Actinobacteria bearing divergent ribosomal drug-binding sites are intrinsi cally resistant to antibiotics (A) Schematic phylogenetic tree showing three closely related branches of Actinobacteria. Each branch exhibits nucleotide variations in the 16S rRNA sequence at the binding sites for two ribo some-targeting antibiotics—spectinomycin and paromomycin. (B–D) Comparison of minimum inhibitory concen trations (MICs) for pactamycin and spectinomycin across representative Actinobacteria, including S. fradiae (bears identical drug-binding residues to E. coli), M. smegmatis (bears A694G substitution in the pactamycin-binding site), and K. subterranea (bears C1192G substitution in the spectinomycin- binding site compared to E. coli). The images show that 16S rRNA nucleotide alterations—previously characterized as resistance conferring in model organisms—correlate with intrinsic drug suscepti bility. Specifically, K. subterranea, which carries the C1192G substitution in spectinomycin-binding site, exhibits intrinsic resistance to spectinomycin (MIC = 20,000 μg/mL), while M. smegmatis (lacking this substitution) exhibits spectinomycin sensitivity (MIC = 20 μg/mL). Conversely, M. smegmatis (bearing A694G substitution in the pactamycin- binding site) can tolerate pactamycin at 62.5 μg/mL concentration, which is 500× higher compared to the concentration required to inhibit the growth of K. subterranea (as shown in Figure S3).

Journal: Cell reports

Article Title: Extensive natural variation in bacterial ribosomal drug-binding sites.

doi: 10.1016/j.celrep.2025.115878

Figure Lengend Snippet: Figure 5. Actinobacteria bearing divergent ribosomal drug-binding sites are intrinsi cally resistant to antibiotics (A) Schematic phylogenetic tree showing three closely related branches of Actinobacteria. Each branch exhibits nucleotide variations in the 16S rRNA sequence at the binding sites for two ribo some-targeting antibiotics—spectinomycin and paromomycin. (B–D) Comparison of minimum inhibitory concen trations (MICs) for pactamycin and spectinomycin across representative Actinobacteria, including S. fradiae (bears identical drug-binding residues to E. coli), M. smegmatis (bears A694G substitution in the pactamycin-binding site), and K. subterranea (bears C1192G substitution in the spectinomycin- binding site compared to E. coli). The images show that 16S rRNA nucleotide alterations—previously characterized as resistance conferring in model organisms—correlate with intrinsic drug suscepti bility. Specifically, K. subterranea, which carries the C1192G substitution in spectinomycin-binding site, exhibits intrinsic resistance to spectinomycin (MIC = 20,000 μg/mL), while M. smegmatis (lacking this substitution) exhibits spectinomycin sensitivity (MIC = 20 μg/mL). Conversely, M. smegmatis (bearing A694G substitution in the pactamycin- binding site) can tolerate pactamycin at 62.5 μg/mL concentration, which is 500× higher compared to the concentration required to inhibit the growth of K. subterranea (as shown in Figure S3).

Article Snippet: Freeze-dried cell pellets of S. fradiae (DSM 40063), obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ), were rehydrated in 1 mL of distilled water.

Techniques: Binding Assay, Sequencing, Comparison, Concentration Assay

Figure 6. rRNA substitutions that cause drug resistance in model organisms are widespread among natural bacterial species (A) rRNA secondary structure diagrams illustrate divergence in the evernimicin-binding pocket between S. fradiae and E. coli ribosomes. (B) Cryo-EM map of S. fradiae shows the divergent drug-binding site. (C) Comparison of experimental and AlphaFold3-predicted structures of S. fradiae’s evernimicin-binding pocket reveals nearly identical conformations (all-atom RMSD = ∼0.3 A˚ ), validating AlphaFold’s utility for assessing rRNA substitution effects. (D) Superposition of vacant S. fradiae ribosome with evernimicin-bound E. coli structure. (E–P) Comparisons of wild-type E. coli binding sites with AlphaFold3-predicted divergent sites across species demonstrate how rRNA variation alters pocket conformation, with each box summarizing the reported drug affinity impacts of substitutions and phylogenetic distribution of variants. Asterisks indicate sequence variants that have a variable impact on drug affinity that depends on the surrounding context in rRNA. (E)–(J) correspond to the large subunit and (K)–(P) to the small subunit. Overall, (E)–(P) show that changes at the direct ribosome-drug interface—even in the absence of apparent steric clashes or disrupted hydrophobic stacking interactions—typically lead to resistance.

Journal: Cell reports

Article Title: Extensive natural variation in bacterial ribosomal drug-binding sites.

doi: 10.1016/j.celrep.2025.115878

Figure Lengend Snippet: Figure 6. rRNA substitutions that cause drug resistance in model organisms are widespread among natural bacterial species (A) rRNA secondary structure diagrams illustrate divergence in the evernimicin-binding pocket between S. fradiae and E. coli ribosomes. (B) Cryo-EM map of S. fradiae shows the divergent drug-binding site. (C) Comparison of experimental and AlphaFold3-predicted structures of S. fradiae’s evernimicin-binding pocket reveals nearly identical conformations (all-atom RMSD = ∼0.3 A˚ ), validating AlphaFold’s utility for assessing rRNA substitution effects. (D) Superposition of vacant S. fradiae ribosome with evernimicin-bound E. coli structure. (E–P) Comparisons of wild-type E. coli binding sites with AlphaFold3-predicted divergent sites across species demonstrate how rRNA variation alters pocket conformation, with each box summarizing the reported drug affinity impacts of substitutions and phylogenetic distribution of variants. Asterisks indicate sequence variants that have a variable impact on drug affinity that depends on the surrounding context in rRNA. (E)–(J) correspond to the large subunit and (K)–(P) to the small subunit. Overall, (E)–(P) show that changes at the direct ribosome-drug interface—even in the absence of apparent steric clashes or disrupted hydrophobic stacking interactions—typically lead to resistance.

Article Snippet: Freeze-dried cell pellets of S. fradiae (DSM 40063), obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ), were rehydrated in 1 mL of distilled water.

Techniques: Binding Assay, Cryo-EM Sample Prep, Comparison, Sequencing